menu
    • menu
    [{"orgOrder":0,"company":"EnPlusOne Biosciences","sponsor":"Wyss Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"RNA-based Therapy","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"EnPlusOne Biosciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"EnPlusOne Biosciences \/ Wyss Institute","highestDevelopmentStatusID":"3","companyTruncated":"EnPlusOne Biosciences \/ Wyss Institute"},{"orgOrder":0,"company":"EnPlusOne Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Inclisiran","moa":"PCSK9","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"EnPlusOne Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"EnPlusOne Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"EnPlusOne Biosciences \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by EnPlusOne Biosciences

    Menu

    EnPlusOne Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            EnPlusOne Biosciences

                            U.S.A arrow
                            DCAT Week
                            Not Confirmed

                            EnPlusOne Biosciences

                            U.S.A arrow
                            DCAT Week
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RNA-based Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : Wyss Institute

                            Deal Size : $27.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            EnPlusOne Collaborates with Wyss on $27 Million ARPA-H RNA Platform Project

                            Details : The collaboration aims to develop a disease-agnostic novel RNA therapeutic with the potential to treat diverse diseases, including types of cancer and infectious diseases.

                            Product Name : Undisclosed

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            August 15, 2024

                            Lead Product(s) : RNA-based Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : Wyss Institute

                            Deal Size : $27.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            EnPlusOne Biosciences

                            U.S.A arrow
                            DCAT Week
                            Not Confirmed

                            EnPlusOne Biosciences

                            U.S.A arrow
                            DCAT Week
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Inclisiran

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            EnPlusOne Biosciences Reveals Breakthrough Enzymatic Synthesis of Leqvio® Antisense Strand

                            Details : Leqvio (inclisiran), approved in over 80 countries, is the first and only approved Small interfering RNA therapy with a successful synthesis of the antisense strand of this drug.

                            Product Name : Leqvio

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            July 09, 2024

                            Lead Product(s) : Inclisiran

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth